Does Pfizer’s Xeljanz share its CV safety questions with burgeoning JAK class?
The 2019 pipeline report: Changing the treatment paradigm
The 20 Hottest Pipeline Drugs to Watch in 2019
Biopharma in 2019
Drugmakers vie to capture slice of rheumatoid arthritis market
2018 is already half over, but expect fireworks now that President Trump has turned his attention to seeking lower drug prices. The Tweeter-in-Chief publicly shamed companies that have tried to … Continue Reading 7 companies to watch during Q2 earnings
While we mostly think of disease as being caused by bacteria or viruses, an illness can often occur when the body’s own defenses turn against itself. Here we’ll take a … Continue Reading Let’s Take a Closer Look at Seven Rare Autoimmune Diseases You Should Know